| アブストラクト | ObjectiveInterleukin-23 (IL-23) inhibitors are widely used for psoriasis and inflammatory bowel disease, yet their long-term safety profiles require continual monitoring. This retrospective observational real-world study aimed to detect potential disproportionate reporting signals associated with tildrakizumab, risankizumab, and guselkumab using the FDA Adverse Event Reporting System (FAERS).MethodsAE reports for tildrakizumab, risankizumab, and guselkumab from Q3 2017 to Q3 2025 were retrieved from FAERS. Disproportionality analysis using reporting odds ratios (RORs) was performed, and reported adverse events were classified by system organ classes (SOCs).ResultsA total of 1124, 8574, and 14597 AEs were retrieved for the three IL-23 inhibitors, generating 42, 286, and 348 disproportionate reporting signals, and accumulating 23, 24, and 24 SOCs. Frequently reported AEs included drug ineffectiveness, psoriasis, injection-site reactions, and infections. Disproportionate reporting signals not listed in the current FDA-approved product label comprised cardiovascular events (e.g., myocardial infarction; tildrakizumab ROR = 6.45), malignancies (e.g., malignant melanoma; risankizumab ROR = 8.57), hepatobiliary disorders, and renal complications.ConclusionThese exploratory, hypothesis-generating disproportionate reporting signals may inform routine pharmacovigilance practice for IL-23 inhibitors, alongside well-established common reported events such as infections and systemic reactions. Further pharmacoepidemiologic studies are needed to validate these observations. |
|---|
| ジャーナル名 | Science progress |
|---|
| Pubmed追加日 | 2026/10/19 |
|---|
| 投稿者 | Guo, Chiwei; Geng, Tiantian; Ye, Luzhen; Sun, Zhonghua; Zhao, Shujuan |
|---|
| 組織名 | Department of Pharmacy, Henan Provincial People's Hospital, People's Hospital of;Zhengzhou University, Zhengzhou, Henan Province, China. RINGGOLD: 12636;School of Clinical Medicine, Henan University, Zhengzhou, Henan Province, China.;Department of Endocrinology, The First People's Hospital of Nankang District,;Ganzhou, Jiangxi Province, China.;Department of Basic Nursing Teaching and Research Section, Jiangxi University of;Technology, Nanchang, Jiangxi Province, China.;Department of Respiratory Medicine, the Fourth Affiliated Hospital of Nanchang;University, Nanchang, Jiangxi Province, China. RINGGOLD: 621994;Department of Medical, School of Nanjing University, Nanjing, Jiangshu, China.;RINGGOLD: 12581 |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/42896048/ |
|---|
